// App-Quantinova.ai

707 : Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance

Researchers

Presenter

  • Pietro R Di Ciaccio

Principal Investigators

  • Kate Cwynarski

  • Cathy Burton

  • Awachana Jiamsakul

  • Mark Bower

  • John Kuruvilla

  • Silvia Montoto

  • Pam McKay

  • Wendy Osborne

  • Sam Milliken

  • Kim Linton

  • Kate Manos

  • Shireen Kassam

  • Nicole Wong Doo

  • Anne-Marie Watson

  • Pasquale L Fedele

  • Costas K. Yannakou

  • Stewart Hunt

  • Hanna Renshaw

  • Nisha Thakrar

  • Alexandra Smith

  • Daniel Painter

  • Alice Maxwell

  • Qin Liu

  • Rageshri Dhairyawan

  • Graeme Ferguson

  • Keir Pickard

  • Nada Hamad

Medical Centers

  • Department of Haematology and Bone Marrow Transplantation, Westmead Hospital, Sydney, Australia

  • The University of New South Wales, NSW, Australia

  • The Kirby Institute, University of New South Wales Australia, Sydney, NSW, Australia

  • Department of Medical Oncology, University College London Hospital, London, United Kingdom

  • Department of Diabetes and Endocrinology, St James University Hospital, Leeds, United Kingdom

  • National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London, United Kingdom

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Division of Haemato-Oncology, St Bartholomews Hospital, Barts Health NHS Trust, London, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom

  • The Christie Hospital, Manchester, United Kingdom

  • University of Manchester, Manchester, United Kingdom

  • Manchester Academic Health Science Centre, St Mary's Hospital, Manchester, United Kingdom

  • Department of Clinical Haematology, Austin Hospital, Melbourne, Australia

  • Kings College London, London, United Kingdom

  • Concord Repatriation General Hospital, Sydney, Australia

  • University of NSW, Sydney, Australia

  • Department of Haematology, Concord Hospital, Sydney, Australia

  • School of Clinical Sciences, Monash University, Melbourne, Australia

  • Haematology Department, Monash Health, Clayton, Australia

  • Department of Molecular Oncology and Cancer Immunology,Epworth HealthCare,Melbourne,Australia

  • Department of Medical Oncology, Gold Coast University Hospital, Gold Coast, QLD, Australia

  • Kings College London, London, United Kingdom

  • Epidemiology and Cancer Statistics Group, Department of Health Sciences,University of York,York,United Kingdom

  • Epidemiology and Cancer Statistics Group, Department of Health Sciences,University of York,York,United Kingdom

  • Chelsea and Westminster Hospital, London, United Kingdom

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Department of Infection and Immunity, Barts Health NHS Trust, London, E1 2BB, United Kingdom

  • Department of Haematology,Beatson West of Scotland Cancer Centre,Glasgow,United Kingdom

  • Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia

  • Department of Haematology, Concord Hospital, Sydney, Australia

Locations

  • Australia

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lymphomas

Biomarkers

  • Cluster of Differentiation 30

  • cMYC

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multinational

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved